SCHEMBL4735281

SCHEMBL4735281

COc1ccc(-c2ccc(NC(=O)Nc3cccc(C)c3)cc2)c2c(N)onc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.65
FLT3 P36888 17/20 0.65
KIT P10721 14/20 0.65
PDGFRB P09619 4/20 0.63
FLT1 P17948 9/20 0.61
CSF1R P07333 8/20 0.61
AURKA O14965 6/20 0.61
ROCK2 O75116 6/20 0.61
LCK P06239 6/20 0.61
RPS6KB1 P23443 6/20 0.61
FLT4 P35916 6/20 0.61
AURKB Q96GD4 6/20 0.61
RPS6KA5 O75582 5/20 0.61
RET P07949 5/20 0.61
FGFR1 P11362 5/20 0.61
FER P16591 5/20 0.61
FRK P42685 5/20 0.61
BLK P51451 5/20 0.61
RPS6KA3 P51812 5/20 0.61
MAP4K2 Q12851 5/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740457 0.91 FLT3 (0.60) KDRFLT3KITPDGFRBFLT1
SCHEMBL4738551 0.90 KDR (0.66) KDRFLT3KITPDGFRBFLT1
SCHEMBL4739605 0.90 KDR (0.67) KDRFLT3KITPDGFRBFLT1
SCHEMBL1384165 0.90 FLT3 (0.59) KDRFLT3KITPDGFRBFLT1
SCHEMBL4735873 0.90 KDR (0.64) KDRFLT3KITPDGFRBFLT1
SCHEMBL1379867 0.90 KDR (0.77) KDRFLT3KITPDGFRBFLT1
SCHEMBL1379843 0.90 KDR (0.77) KDRFLT3KITPDGFRBFLT1
SCHEMBL4735702 0.87 KDR (0.78) KDRFLT3KITPDGFRBFLT1
SCHEMBL419413 0.86 KDR (0.81) KDRFLT3KITPDGFRBFLT1
SCHEMBL1384151 0.86 KDR (0.65) KDRFLT3KITPDGFRBFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed